Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3483980 | 0.74 | LMNA (0.43) | CYP3A4ARAURKAROCK2CSF1R | |
| SCHEMBL3403550 | 0.74 | EGFR (0.48) | CYP3A4CSF1RFLT1RPS6KB1KDR | |
| SCHEMBL4797458 | 0.72 | ADORA2A (0.43) | CYP3A4ARMEN1KMT2ATSHR | |
| SCHEMBL1964539 | 0.72 | CYP3A4 (0.56) | CYP3A4PDE7AMEN1KMT2ATSHR | |
| SCHEMBL25500740 | 0.71 | AR (0.60) | CYP3A4ARPDE7AMEN1KMT2A | |
| SCHEMBL632218 | 0.70 | CYP3A4 (0.46) | CYP3A4ARPDE7AEGFRERBB2 | |
| SCHEMBL3484983 | 0.70 | EGFR (0.46) | CYP3A4ARPDE7AEGFRERBB2 | |
| SCHEMBL22069692 | 0.70 | RHEB (0.45) | CYP3A4ARPDE7AMEN1KMT2A | |
| SCHEMBL2880026 | 0.68 | GAA (0.55) | AURKAROCK2CSF1RFGFR1FLT1 | |
| SCHEMBL1660675 | 0.68 | RHEB (0.37) | CYP3A4PDE7AMEN1KMT2AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253633-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-20090233937-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233937-A1 | FUSED HETEROCYCLIC COMPOUND | ROS1, JAK2, ERBB2 | CYP3A4 1677/4885AR 390/4885AURKA 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.